Literature DB >> 8001008

Non-Hodgkin's lymphoma.

T C Greiner1, L J Medeiros, E S Jaffe.   

Abstract

BACKGROUND: Significant advances in the understanding of non-Hodgkin's lymphoma (NHL) have occurred in the past two decades, resulting in changes in terminology and classification practices, which may affect the analysis of the Surveillance, Epidemiology, and End Results (SEER) data.
METHODS: The incidence rates for each subgroup of NHL in the Working Formulation were reviewed from the National Cancer Institute's SEER data during three time periods: 1973-1977, 1978-1982, and 1983-1987.
RESULTS: NHL has significantly increased by 50% from 1973 to 1988. The most frequently occurring NHL is diffuse large cell lymphoma, constituting nearly 30% of all lymphomas. Increased incidence rates for large cell immunoblastic and small noncleaved cell NHL observed during the 1980s are attributable largely to the acquired immunodeficiency syndrome epidemic. Exposure to environmental agents such as herbicides and hair coloring dyes have recently been identified as factors that increase the risk of NHL, but the overall contribution of these factors remains to be identified. The increase in extranodal lymphomas is in part a consequence of the application of modern immunophenotypic and genotypic methods, which lead to the reclassification of pseudolymphomas as monoclonal B-cell neoplasms. The apparent dramatic decline in the incidence of diffuse small cleaved NHL appears to be artifactual, as well, secondary to changes in classification of NHL.
CONCLUSIONS: With the enhanced ability of pathologists to delineate new clinicopathologic entities by immunophenotypic and molecular biologic studies, future modifications to the collection of SEER data may be appropriate. Such an approach will address the limitations of the Working Formulation and lead to a more accurate data base for the evaluation of epidemiologic trends.

Entities:  

Mesh:

Year:  1995        PMID: 8001008     DOI: 10.1002/1097-0142(19950101)75:1+<370::aid-cncr2820751319>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma.

Authors:  Mayumi Mori; Kiyoshi Kitamura; Michihiko Masuda; Tomomitsu Hotta; Tamotsu Miyazaki; Akira B Miura; Hideaki Mizoguchi; Akira Shibata; Hidehiko Saito; Tamotsu Matsuda; Toru Masaoka; Mine Harada; Yoshiyuki Niho; Fumimaro Takaku
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 3.  Low-grade lymphomas: new entities and treatment concepts.

Authors:  F B Hagemeister
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

4.  Role of stem-cell divisions in cancer risk.

Authors:  Cristian Tomasetti; Rick Durrett; Marek Kimmel; Amaury Lambert; Giovanni Parmigiani; Ann Zauber; Bert Vogelstein
Journal:  Nature       Date:  2017-08-09       Impact factor: 49.962

5.  A collaborative nationwide lymphoma study in Lebanon: incidence of various subtypes and analysis of associations with viruses.

Authors:  Zaher K Otrock; Jad Saab; Georges Aftimos; Fady Nasr; Fadi S Farhat; Saad Khairallah; Gérard Abadjian; Marwan Ghosn; Hassan Sidani; Ahmad Ibrahim; Ayman Tawil; Claude Ghorra; Zarouhie Meguerian; Walid Mokaddem; Walid Dayeh; Ziad Salem; Georges Chahine; Nizar Bitar; Anas Mugharbel; Joseph Makdessi; Christina Khater; Mirna El Hajj; Dany Abi Gerges; Charles Sfeir; Joseph Kattan; Khaled Ibrahim; Michel Saade; Hussein Sadek; Rami A Mahfouz; Mohamed A Kharfan-Dabaja; Ghazi Zaatari; Ali Bazarbachi
Journal:  Pathol Oncol Res       Date:  2013-05-08       Impact factor: 3.201

Review 6.  Radioimmunotherapy for Non-Hodgkin's Lymphoma.

Authors:  Arati V Rao; Gamal Akabani; David A Rizzieri
Journal:  Clin Med Res       Date:  2005-08

7.  Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Authors:  Changhoon Yoo; Shin Kim; Byeong Seok Sohn; Jeong-Eun Kim; Dok Hyun Yoon; Jooryung Huh; Dae Ho Lee; Sang-We Kim; Jung-Shin Lee; Cheolwon Suh
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

8.  Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.

Authors:  YanGuo Kong; Gustavo A Barisone; Ranjit S Sidhu; Robert T O'Donnell; Joseph M Tuscano
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

9.  Histiocytic and t-cell rich b-cell lymphoma (TCRBCL) of the stomach.

Authors:  J Tóth; G Elek
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

10.  Lack of Bcl-2 expression in feline follicular lymphomas.

Authors:  Manfred Henrich; Anna Bauknecht; Werner Hecht; Manfred Reinacher
Journal:  J Vet Diagn Invest       Date:  2019-10-04       Impact factor: 1.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.